One month since our Q1 meeting hosted by @guardanthealth.bsky.social in San Diego!

Whether advancing key deliverables or exploring what’s next for BLOODPAC, the conversations were engaging, productive, and full of energy.

#BLOODPAC #LiquidBiopsy

#StanDOM's Dr. Ash Alizadeh leads Cancer Genomics at Stanford Cancer Institute. His recent #MedicineGrandRounds showcased breakthrough liquid biopsy & AI research transforming cancer diagnosis, surveillance & treatment.

📷: Clinton Louie

#CancerGenomics #LiquidBiopsy

This commentary proposes a stratified sequential strategy that preserves Fecal Immunochemical Test based efficiency while using liquid biopsy only to rescue persistent non-responders.
doi.org/10.59717/j.x...
#OncologyResearch #liquidbiopsy #ColorectalCancer

🎙️ On Target | New Episode: #SusanTousi CEO, DELFI Diagnostics.

Susan Tousi, CEO of #DELFIDiagnostics, shares how her company is using #AI & #fragmentomics to make #liquidbiopsy more accessible, cancer less deadly.

🎧 lnkd.in/emNwrShj

#OnTarget #HealthcareInnovation

Infographic on colorectal cancer prevention and screening. Covers five prevention tips (diet, exercise, avoiding risk factors, knowing family history, and recognising symptoms), a screening timeline starting at age 45, the 90–95% survival rate when caught early, and an introduction to liquid biopsy as a future detection method.

The future of detection is a simple blood test. Liquid biopsy can pick up tumour signals before symptoms appear — no invasive procedure needed. That's what ColoMARK is working toward. We're not there yet. But this month reminds us why the work matters. #EarlyDetection #LiquidBiopsy #CancerPrevention

📚 New Review for your weekend reading!

Liquid biopsy epigenetics: establishing a molecular profile based on cell-free DNA

🔓 buff.ly/4a4AmPZ

#Epigenetics #LiquidBiopsy #CellFreeDNA #cfDNA

New masterclass now available 🎥

Klaus Pantel & Catherine Alix-Panabières provide an in-depth overview of liquid biopsy diagnostics: From early detection to clinical implementation.

Watch here: https://youtu.be/uFuAvdRABTo

#LiquidBiopsy #CancerResearch #PANCAID

Collect. Preserve. Ship.
All in 5 simple steps.
Room temp preservation for DNA & RNA with minimal handling.
🔗 norgenbiotek.com/product/urin...
#LiquidBiopsy #Genomics

🔬 Session Highlight: Liquid Biopsies & Early Detection
11th International Congress on Cancer Science and Radiology 2026
📅 July 22–23, 2026
📍 Hilton Tokyo Hotel, Tokyo, Japan
🌐 cancertherapy.inovineconferences.com

#cancerscience2026 #liquidbiopsy #earlydetection #ce

We’re at the BZI Show at Juravinski Hospital today.

Come meet Giuseppe & Aida and chat all things RNA, DNA, and exosomes.

#BZIShow #LiquidBiopsy

By combining cfDNA analysis with RNA extraction for miRNA workflows, they moved closer to a multi-analyte liquid biopsy approach.

A great example of how secondments can spark new ideas, shared protocols, and richer molecular insights.

#LiquidBiopsy #PrecisionMedicine

#cancer #earlydetection
#liquidbiopsy

Chromatin unwinding state for in situ identification and lineage tracing of circulating tumor cells The detection of circulating tumor cells (CTCs) through liquid biopsy offers a non-invasive approach for accurately monitoring cancer dissemination and evaluating therapeutic efficiency. However, the...

🚀 New breakthrough in cancer detection!
Chromatin unwinding state for in situ identification and lineage tracing of circulating tumor cells
#CancerResearch #LiquidBiopsy #PanCTC #CancerDetection #AIinMedicine
onlinelibrary.wiley.com/doi/10.1002/...

Liquid Biopsy Research Summary February 2026 - Summarized Science Summary of key Liquid Biopsy publications highlighting major findings, clinical relevance, and emerging research trends.

🩸 Liquid Biopsy - Feb 2026

• Pan-cancer analysis identifies 14,202 methylation regions for cancer detection
• Multi-omics integration boosts cancer detection sensitivity in PROMISE study
• M-PACT classifies pediatric CNS tumors from low-input cfDNA

pir.sh/32p17rmgwv

#LiquidBiopsy #ctDNA

AI Liquid Biopsy Detects Early Liver Fibrosis and Cirrhosis Before Symptoms Researchers at Johns Hopkins Kimmel Cancer Center have developed an AI-driven blood test capable of detecting early liver fibrosis and cirrhosis years before symptoms appear. The technology, called fragmentome analysis, examines genome-wide patterns of cell-free DNA (cfDNA) fragments circulating in the blood. Unlike traditional liquid biopsies that look for specific mutations, this method analyzes how DNA fragments are broken and distributed, capturing hidden signals of overall health. Using whole-genome sequencing of cfDNA from over 1,500 individuals with liver conditions and other medical issues, the AI system identifies fragmentation patterns linked to disease. This approach showed high sensitivity for early liver disease detection, offering the potential to intervene before fibrosis progresses to cirrhosis or increases the risk of liver cancer. The researchers also created a fragmentome-based comorbidity index, which predicted overall survival and could be applied to other chronic diseases. While the liver fibrosis test remains a prototype, this method may eventually extend to cardiovascular, inflammatory, and neurodegenerative conditions, opening new possibilities for early diagnosis and preventive care.

AI Liquid Biopsy Detects Early Liver Fibrosis and Cirrhosis Before Symptoms

🤖 IA: It's not clickbait ✅
👥 Usuarios: It's not clickbait ✅

#liverdisease #aidiagnostics #liquidbiopsy

View full AI summary:

Watch Session 1 of LBCA’s Liquid Biopsy webinar series to learn how these tests are being used in ILC treatment: lobularbreastcancer.org/liquid-biops... #lobularbreastcancer #ILC #liquidbiopsy

Joaquín Mateo, Judith Balmaña, and Cristina Saura receive #PERIS grants from Department of Health of the Government of Catalonia to strengthen their research in metastatic prostate cancer, #BreastCancer risk, and early diagnosis with #LiquidBiopsy in breast milk.

➡️ https://linke.to/PERISGrantsVHIO

What Is Cytoplasmic and Nuclear RNA Purification? What Is Cytoplasmic and Nuclear RNA Purification?

RNA localization shapes gene regulation. Learn how cytoplasmic and nuclear RNA purification strengthens ncRNA biomarker interpretation across cancer and cardiovascular research.
Read the full blog: norgenbiotek.com/blog/what-cy...
#RNA #LiquidBiopsy

cfGWAS reveal genetic basis of cell-free DNA end motifs - Nature Communications Cell-free DNA is widely used in clinical testing, but its genetic basis remains unclear. Here, the authors perform cfGWAS in 28,016 pregnant women, identifying 15 loci linked to cfDNA end motifs and c...

Can we reuse NIPT cfDNA datasets to decode cfDNA biology? Nature Communications presents the first large-scale cfGWAS (28,016 pregnancies), revealing genetic regulators of cfDNA end motifs - promising for better liquid biopsy design. doi.org/10.1038/s414...

#cfDNA #cfGWAS #LiquidBiopsy #Genomics

Liquid biopsies hold promise as companion diagnostics or surrogate endpoints in clinical trials. How does the current regulatory landscape pose challenges for pharma? Read the recent developments in our latest edition of the Liquid Biopsy Playbook. Download now: hubs.la/Q03PFMSp0 #liquidbiopsy

Liquid biopsy and molecularly driven therapies for colorectal cancer: current and future applications in precision oncology - Tumori Journal If we were to stop at a first glance, the use of liquid biopsy would be limited in the clinical practice of colorectal cancer to cases where tumour tissue is unavailable or insufficient. In reality,…

🎙️Find out how #liquidbiopsy is the new goal of #precisiononcology, capable of technologically and culturally revolutionising clinical practice in this TJ Talks podcast with Prof. Andrea Sartore Bianchi, Milan

omny.fm/shows/tumori...

#CanSky #OncoSky

M-PACT leverages cell-free DNA methylomes to achieve robust classification of pediatric brain tumors - Nature Cancer Smith et al. present M-PACT, a deep neural network leveraging low-input cell-free DNA methylation profiles to achieve robust classification of pediatric brain tumors and enable cellular deconvolution ...

Excited to share our latest work—establishing a pipeline for DNA methylation–based CNS tumor diagnostics from minimally invasive CSF liquid biopsies—published today in Nature Cancer! Huge thanks to all collaborators. www.nature.com/articles/s43... #LiquidBiopsy #PediatricNeuroOncology #TeamScience

Transfer RNA-derived small RNAs (tsRNAs): A rising star in liquid biopsy

This review characterizes tsRNAs as high-potential #Biomarkers for #LiquidBiopsy, detailing their biogenesis and stability in biofluids, their roles in disease #Pathogenesis, and their application as non-invasive biomarkers.
#OpenAccess: doi.org/10.1016/j.ge...

Liquid Biopsy Research Summary January 2026 - Summarized Science Summary of key Liquid Biopsy publications highlighting major findings, clinical relevance, and emerging research trends.

🧪 Liquid Biopsy — Jan 2026

• Post-treatment ctDNA predicts recurrence across multiple cancers
• Baseline mutation status refines prognosis in advanced disease
• CTCs and EV-derived signals guide therapy response

pir.sh/A5kgYmGg4m

#LiquidBiopsy #ctDNA #PrecisionOncology #CancerDiagnostics

Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection - Nature Reviews Cancer In this Review, Bruhm et al. provide a comprehensive overview of targeted and genome-wide cell-free DNA detection approaches, examining their potential to complement existing screening programmes or enhance early cancer detection for those cancers without effective screening methods.

🥳 Our 8th most downloaded #REVIEW in 2025:

Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection

#cfDNA #liquidbiopsy @NatResCancer
#NRCtop10of2025

Detecting early-stage cancers with a liquid biopsy measuring epigenetic instability – BioNews Central A novel liquid biopsy method using a new metric, the Epigenetic Instability Index, accurately distinguishes patients with early-stage lung and breast cancers from healthy individuals. ...

A novel #LiquidBiopsy method using a new metric, the #EpigeneticInstability Index, accurately distinguishes patients with early-stage lung and #BreastCancers from healthy individuals.
#EarlyDetection #LungCancer

📍 ScreenCell® at the PSCC Innovation Forum 2026!

We’ll be in Villejuif on February 4.

Our Technical Sales Manager, Emile Lakis, PhD, will be available for B2B meetings and to present our #circulatingtumorcell isolation technology.

#liquidbiopsy

Still spinning samples for hours just to get inconsistent exosomes?
Norgen’s Exosome Purification Kits isolate intact exosomes from plasma, serum, urine, and cell culture media in under 30 minutes, without ultracentrifugation.
norgenbiotek.com/product/exos...
#Exosomes #LiquidBiopsy

📍 ScreenCell at SU2C Scientific Summit 2026!

Our CTO Sina NASERIAN, Ph.D. will present : "Transforming Cancer Monitoring: The Impact of #CirculatingTumorCells"

🗓️ Jan 31 | 2:45-3:00 PM PST
📍 Session 4: Minimally Invasive Measurements

#LiquidBiopsy

@su2c.bsky.social
@screencell.bsky.social

The image shows an anatomical diagram depicting T1 gastric cancer and its metastasis to lymph nodes, along with an overview of a cell-free DNA methylation-based liquid biopsy assay to identify lymph node metastasis.

🧪🩸 #LiquidBiopsy may help avoid surgery in early #GastricCancer

🔸cfDNA methylation predicts lymph node metastasis in T1 gastric cancer
🔸Combined model achieved AUC 0.86
🔸Up to 44% of patients could avoid invasive surgery

Read more in UEG Journal 👉 https://bit.ly/4sKDDA6